Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Aim(s): To analyze RECIST-response to second-line chemotherapy as a function of antitumor activity and type of first line chemotherapy.
Materials and methods: Multicenter retrospective study. Inclusion criteria were: 1)Confirmed pNET naive of therapy 2)RECIST measurable disease 3)Sporadic tumor. STZ- and DCZ- regimens were grouped together as alkylating agents.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Marotta V
To read the full abstract, please log into your ENETS Member account.